Table 1 Participants characteristics
From: A continuous approach to explain insomnia and subjective-objective sleep discrepancy
Variables | SOSD− (n = 624) | SOSD+ (n = 199) | GS (n = 104) | |
|---|---|---|---|---|
Anthropometric data | Sex (% female) | 69.7 (n = 435) | 74.4 (n = 148) | 30.8 (n = 32) |
Age (years) | 46.8 ± 14.1 | 40.8 ± 12.1 | 36.2 ± 11.9 | |
BMI (kg/m2) | 23.1 ± 3.86 | 23.0 ± 3.56 | 24.2 ± 2.61 | |
Comorbidities | Smoking (%) | 21.8 | 23.6 | 27.3 |
Depression (%) | 25.0 | 22.0 | 0.0 | |
Anxiety (%) | 19.0 | 19.4 | 0.0 | |
Cardiovascular disease (%) | 13.8 | 5.2 | 0.0 | |
Pulmonary disease (%) | 5.2 | 5.2 | 3.6 | |
Gastrointestinal disease (%) | 4.4 | 4.0 | 0.0 | |
Infectious disease (%) | 1.3 | 0.6 | 0.0 | |
Metabolic disease (%) | 10.5 | 7.5 | 0.0 | |
Cancer (%) | 3.7 | 1.8 | 0.0 | |
Covid (%) | 3.3 | 3.2 | 0.0 | |
Epilepsy (%) | 0.8 | 1.2 | 0.0 | |
Pain (%) | 7.4 | 8.6 | 0.0 | |
Other comorbidity (%) | 38.3 | 36.8 | 17.9 | |
Treatments | Antidepressant (%) | 23.0 | 23.1 | 0.0 |
Antihistamine (%) | 10.2 | 9.5 | 0.0 | |
Antipsychotic (%) | 3.3 | 4.1 | 0.0 | |
Benzodiazepine (%) | 25.0 | 24.9 | 0.0 | |
Melatonin (%) | 6.7 | 7.1 | 0.0 | |
Z-drugs (%) | 14.6 | 11.8 | 0.0 | |
Opioid (%) | 0.6 | 0.6 | 0.0 | |
RLS medication (%) | 1.2 | 0.6 | 0.0 | |
Other medication (%) | 41.1 | 39.6 | 3.6 | |
